Liability for inaccurate diagnostic tests in mass screening

Introduction

Liability for inaccurate diagnostic tests in mass screening concerns legal responsibility when a large-scale screening program produces false-positive, false-negative, unreliable, or improperly interpreted results, causing injury to individuals or exposing them to unnecessary medical interventions. Mass screening differs from ordinary individual diagnosis because testing is performed on a large population, often involving people who have no symptoms.

Examples include population-wide screening for infectious diseases, cancer, genetic conditions, metabolic disorders, and occupational exposure. Because screening tests are generally designed to identify people who may require further investigation rather than to provide a definitive diagnosis, an inaccurate result does not automatically establish negligence. Liability depends upon the applicable standard of care, the quality of the test, the circumstances of its use, and the causal connection between the error and the resulting harm.

Nature of diagnostic-test liability

A diagnostic error may occur at several stages:

1. Test design or manufacture — the test itself may be defective or inadequately validated.
2. Laboratory performance — the laboratory may incorrectly collect, process, analyze, or report the sample.
3. Interpretation — healthcare professionals may incorrectly interpret a result.
4. Communication — a significant result may not be communicated appropriately.
5. Follow-up — a positive screening result may not be followed by appropriate confirmatory testing.

Liability may consequently involve manufacturers, laboratories, healthcare professionals, hospitals, government screening programs, or multiple parties.

Screening versus diagnosis

A central legal distinction is between screening and diagnosis. A screening test is usually intended to identify individuals who may have a disease or risk condition. It may have imperfect sensitivity and specificity.

Therefore, a positive screening result normally requires confirmatory investigation, while a negative result may not completely eliminate the possibility of disease.

A screening provider should communicate these limitations where they are material. Presenting a screening test as infallible may create an unreasonable expectation and increase the risk of negligent decision-making.

False-negative results

A false-negative result may be particularly serious because it can delay diagnosis and treatment.

Liability may arise where a reasonably competent laboratory or healthcare professional should have identified the disease or recommended further testing but failed to do so.

However, not every false-negative result constitutes negligence. Courts generally consider the applicable scientific knowledge, test limitations, laboratory standards, clinical circumstances, and whether the error was reasonably avoidable.

False-positive results

False-positive results can cause a different category of harm. A patient may undergo unnecessary invasive procedures, medication, psychological distress, social consequences, or financial costs.

Where a screening provider fails to use an appropriately validated test or improperly treats a preliminary result as a definitive diagnosis, liability may arise if foreseeable harm follows.

The possibility of false positives is particularly important in population screening because even a test with high specificity can produce substantial numbers of false positives when applied to very large populations or low-prevalence groups.

Rogers v Whitaker

The Australian High Court's decision in Rogers v Whitaker (1992) 175 CLR 479 is an important authority concerning medical negligence and disclosure of material risks.

Although it did not concern mass screening specifically, the decision is relevant because it recognizes the importance of communicating material information to patients. Where a diagnostic or screening test has significant limitations or consequences, appropriate communication can form part of the healthcare provider's duty.

The case also demonstrates that professional custom does not necessarily determine the entire scope of the duty owed to a patient.

Bolam and Bolitho

In the United Kingdom, Bolam v Friern Hospital Management Committee (1957) established the traditional approach to assessing professional medical negligence. A medical professional would generally not be negligent if acting according to a responsible body of medical opinion.

The approach was qualified by Bolitho v City and Hackney Health Authority (1997), where the House of Lords emphasized that professional opinion must withstand logical analysis.

These principles can be relevant to diagnostic testing. A clinician may rely upon a recognized testing protocol, but that reliance must still be defensible in light of the circumstances and available evidence.

Montgomery v Lanarkshire Health Board

In Montgomery v Lanarkshire Health Board (2015), the UK Supreme Court significantly developed the law concerning patient information and informed consent.

The Court emphasized the patient's role in decision-making and the duty to take reasonable care to ensure that patients are aware of material risks and reasonable alternatives.

Although the case involved childbirth rather than diagnostic screening, its reasoning is relevant where screening involves significant potential consequences. Patients should receive meaningful information necessary to participate in decisions concerning follow-up testing and treatment.

Product liability for defective diagnostic tests

Where the inaccurate result arises from a defective test kit or diagnostic device, product-liability principles may become relevant.

A manufacturer could potentially face liability for:

• defective design;
• manufacturing defects;
• inadequate quality control;
• failure to validate the test;
• inadequate instructions;
• failure to warn about known limitations; or
• failure to update warnings after discovering significant risks.

The legal treatment of medical diagnostic products varies by jurisdiction.

In the United States, the Food, Drug, and Cosmetic Act provides a regulatory framework for medical devices and in-vitro diagnostic products. Regulatory compliance, however, does not necessarily resolve every civil-liability question.

In re DePuy Orthopaedics

Although not a diagnostic-testing case, product-liability litigation such as In re DePuy Orthopaedics, Inc. Pinnacle Hip Implant Products Liability Litigation demonstrates how courts evaluate complex medical-product evidence, scientific causation, warnings, and expert testimony.

The broader lesson is that technical medical evidence must be evaluated carefully rather than assuming that a medical product's regulatory status conclusively determines civil liability.

Expert evidence and causation

Diagnostic-test litigation frequently depends upon expert scientific evidence.

In Daubert v. Merrell Dow Pharmaceuticals, Inc. (1993), the U.S. Supreme Court established principles governing the admissibility of expert scientific evidence. Courts may consider factors including testability, peer review, potential error rates, and general acceptance.

This becomes important where a claimant argues that an inaccurate screening test caused delayed treatment or unnecessary intervention. Expert evidence may be required to establish whether the test was scientifically reliable and whether a different result would probably have changed the clinical outcome.

Government mass-screening programs

Government-sponsored screening creates additional legal issues. A public authority may have statutory immunity, governmental liability protections, or special procedural requirements depending upon the jurisdiction.

Where screening is mandatory or strongly promoted by government, the state may have additional responsibilities concerning test accuracy, communication of limitations, follow-up systems, and equitable access.

However, the precise liability standard depends upon the applicable legislation. A government entity should not automatically be treated like a private diagnostic laboratory.

Australian legal perspective

In Australia, potential liability may arise under negligence law, the Australian Consumer Law, therapeutic-goods regulation, professional standards, and relevant state and territory legislation.

The High Court's reasoning in Naxakis v Western General Hospital (1999) 197 CLR 269 is relevant to medical negligence and causation. The case demonstrates the importance of examining whether medical decision-making fell below the required standard and whether the relevant conduct caused the injury.

Australian laboratories may also be subject to accreditation requirements administered through NATA, particularly where pathology services are involved.

Allocation of responsibility

Responsibility can be distributed among multiple actors:

Courts generally examine each party's individual duty and contribution to the harm rather than automatically assigning responsibility to the person who performed the test.

Causation and damages

A claimant must generally establish that the inaccurate result caused legally recognizable harm.

For a false negative, this may involve demonstrating that earlier detection would probably have resulted in effective treatment or a materially better outcome.

For a false positive, the claimant may need to demonstrate that the erroneous result caused unnecessary treatment, testing, psychological injury, or other recognized damage.

Causation can become difficult where the underlying disease was already advanced or where the patient would have experienced substantially the same outcome regardless of the screening error.

Governance safeguards

Mass-screening programs should therefore incorporate:

• validated testing methods;
• appropriate sensitivity and specificity standards;
• quality-control systems;
• confirmatory testing for significant results;
• clear patient communication;
• appropriate referral pathways;
• monitoring of false-positive and false-negative rates;
• adverse-event reporting;
• periodic scientific reassessment; and
• mechanisms for correcting inaccurate records.

A screening program should also distinguish between screening results and definitive diagnoses in its communications.

Conclusion

Liability for inaccurate diagnostic tests in mass screening depends upon the interaction of professional negligence, product liability, scientific evidence, informed decision-making, regulatory standards, and causation. A false result by itself does not necessarily establish legal fault because screening technologies have inherent limitations.

Cases such as Rogers v Whitaker, Bolam, Bolitho, Montgomery v Lanarkshire Health Board, Naxakis v Western General Hospital, and Daubert v Merrell Dow Pharmaceuticals provide important principles concerning professional standards, patient information, causation, and scientific evidence.

The strongest governance model recognizes that mass screening is a population-level public-health intervention rather than ordinary individual diagnosis. It therefore requires validated tests, transparent communication of limitations, appropriate confirmatory procedures, quality assurance, competent interpretation, and reliable follow-up systems. Where these safeguards are negligently absent and foreseeable harm results, legal liability may arise against the responsible actors.